Blood cancer (chronic myeloid leukaemia)

Chronic Myeloid Leukaemia (CML) is a type of blood cancer characterized by the overproduction of abnormal white blood cells, known as myeloid cells, in the bone marrow. This accumulation interferes with the production of other essential blood cells, leading to symptoms such as fatigue, frequent infections, and uncontrolled bleeding.
Commonly prescribed medications for managing CML include:

Tyrosine Kinase Inhibitors (TKIs): These oral medications target the BCR-ABL protein, which is responsible for the uncontrolled growth of myeloid cells in CML. Examples of TKIs include Imatinib, Dasatinib, and Nilotinib. These drugs help to control the cancer and improve overall survival rates.
Hydroxyurea: This oral medication works by slowing down the production of blood cells in the bone marrow. It is often used as a short-term treatment to manage symptoms and prepare for more targeted therapies.
Interferon-alfa: This injectable medication helps to regulate the immune system and slow down the growth of cancerous cells. It is typically used in conjunction with other treatments for CML.

Consult with a healthcare professional to determine the most appropriate treatment plan for each individual case of CML. Regular monitoring and follow-up are crucial to ensure the best possible outcome for patients with this condition.